Sep. 27, 2013R&D
Dainippon Sumitomo Pharma submits an application for an atypical antipsychotic blonanserin (Brand name in Japan: LONASEN) in China
Osaka, Japan, September 27, 2013 - Dainippon Sumitomo Pharma Co., Ltd. (“DSP”) (Head Office: Osaka, Japan; President: Masayo Tada) today announced that it has submitted an imported drug registration application in China for an atypical antipsychotic blonanserin (generic name, brand name in Japan: LONASEN®) to China Food and Drug Administration (CFDA) for the treatment of schizophrenia.
The submitted application is based on the positive results obtained in the phase III clinical study, which was conducted in China for blonanserin for patients with schizophrenia.
DSP looks forward to contributing to the treatment of patients with schizophrenia in China by offering a new treatment option when blonanserin is approved in that country.
About blonanserin (brand name in Japan: LONASEN®)
Blonanserin is an atypical antipsychotic agent with novel structure, discovered by Dainippon Sumitomo Pharma. This product is characterized by its strong blocking action and high selectivity against dopamine-2 receptors and serotonin-2 receptors. It has stronger blocking action to dopamine-2 receptors than to serotonin-2 receptors. Consequently, this drug has been found to improve not only positive symptoms of schizophrenia (such as hallucinations and delusions), but also negative symptoms (such as flat affect and hypobulia). In Japan it is available from DSP since April 2008 for the treatment of schizophrenia.